BioStem Technologies's EBIT per Share for the
three
months ended in Sep. 2025 was $0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.41.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioStem Technologies's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioStem Technologies was 80.30% per year. The lowest was -68.10% per year. And the median was 22.10% per year.
BSEM's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.55 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
BioStem Technologies (OTCPK:BSEM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioStem Technologies EBIT per Share Related Terms
BioStem Technologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a EBIT per Share of $0.41 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #999999 out of 1178 companies in the Biotechnology industry.
Is BioStem Technologies' EBIT per Share too high?
BioStem Technologies' current EBIT per Share is $0.41. The Biotechnology industry median EBIT per Share is 15.55. BioStem Technologies' value of $0.41 is 97.4% below this industry median. Based on the distribution chart, BioStem Technologies ranks #999999 out of 1178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' EBIT per Share compare to XLO and TCRX?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #999999 out of 1178 companies for EBIT per Share. This places BioStem Technologies in the lower half of its industry. The industry median EBIT per Share is 15.55. BioStem Technologies' value of $0.41 is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current EBIT per Share of $0.41 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current EBIT per Share is $0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.65, compared to a current price of $3.24 — trading 97.7% below its estimated fair value. The current EBIT per Share is $0.41 and 97.4% below the Biotechnology industry median of 15.55. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current EBIT per Share is $0.41 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.24 is trading 97.7% below its estimated GF Value™ of $141.65.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
EBIT per Share: $0.41
GF Value™: $141.65 vs. price of $3.24 (97.7% below fair value)
Industry Position: 97.4% below the Biotechnology median (#999999 of 1178)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
